Brachytherapy
Volume 7, Issue 1 , Pages 1-6 , January 2008

Combined brachytherapy with external beam radiotherapy for localized prostate cancer: Reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy

  • Michael J. Zelefsky

      Affiliations

    • Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
    • Corresponding Author InformationCorresponding author. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 22, New York, NY 10065, USA. Tel.: +1-212-639-6802; fax: +1-212-639-8876.
    • ,
  • Michele A. Nedelka

      Affiliations

    • Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Zumre-Lutfiye Arican

      Affiliations

    • Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Yoshiya Yamada

      Affiliations

    • Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Gil'ad N. Cohen

      Affiliations

    • Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Alison M. Shippy

      Affiliations

    • Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Jessica J. Park

      Affiliations

    • Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Marco Zaider

      Affiliations

    • Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY

Received 3 October 2007 ,Revised 4 December 2007 ,Accepted 10 December 2007.

References 

  1. Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 2000;18:3904–3911
  2. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA. 2005;294:1233–1239
  3. Peeters STH, Heemsbergen WD, Koper PCM, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized Phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24:1990–1996
  4. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8:475–487
  5. Jani AB, Hand CM, Lujan AE, et al. Biologic effective dose for comparison and combination of external beam and low dose rate interstitial brachytherapy prostate cancer treatment plans. Med Dosim. 2004;29:42–48
  6. Zaider M, Zelefsky MJ, Cohen GN, et al. Methodology for biologically-based treatment planning for combined low dose-rate (permanent implant) and high dose-rate (fractionated) treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 2005;61:702–713
  7. Lee WR, Bae K, Lawton C, et al. Late toxicity and biochemical recurrence after external beam radiotherapy combined with permanent-source prostate brachytherapy: Analysis of Radiation Therapy Oncology Group study 0019. Cancer. 2007;109:1506–1512
  8. Albert M, Tempany CM, Schultz D, et al. Late urinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiotherapy. Cancer. 2003;98:949–954
  9. Kang SK, Chou RH, Dodge RK, et al. Gastrointestinal toxicity of transperineal interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2002;53:99–103
  10. Sarosdy MF. Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy. Cancer. 2004;101:754–760
  11. Zeitlin SI, Sherman J, Raboy A, et al. High dose combination radiotherapy for the treatment of localized prostate cancer. J Urol. 1998;160:91–95
  12. Zelefsky MJ, Yamada Y, Cohen GN, et al. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007;67:65–70
  13. Zelefsky MJ, Yamada Y, Marion C, et al. Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound guided prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;55:956–963
  14. Wust P, von Borczyskowski DW, Henkel T, et al. Clinical and physical determinants for toxicity of I-125 seed prostate brachytherapy. Radiother Oncol. 2004;73:39–48
  15. Prada PJ, Juan G, Fernandez J, et al. Conformal prostate brachytherapy guided by realtime dynamic dose calculations using permanent 125-Iodine implants-technical description and preliminary experience. Arch Esp Urol. 2006;59:933–940
  16. Stone NN, Stock RG. Long-term urinary, sexual and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology. 2007;69:338–342
  17. Zelefsky MJ, Chan H, Hunt M, et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006;176:1415–1419
  18. Thames H, Kuban D, Levy L, et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003;57:929–943
  19. Singh A, Zelefsky MJ, Raben A, et al. Combined 3-dimensional conformal radiotherapy and transperineal Pd-103 permanent implantation for patients with intermediate and unfavorable risk prostate cancer. Int J Cancer. 2000;90:275–280
  20. Zaider M, Zelefsky MJ, Cohen GN, et al. The role of external beam in brachytherapy. Future Oncol. 2007;3:159–168
  21. Gelblum DY, Potters L, Ashley R, et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys. 1999;45:59–67
  22. Ghaly M, Wallner K, Merrick G, et al. The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: Morbidity outcomes from two prospective randomized multicenter trials. Int J Radiat Oncol Biol Phys. 2003;55:1288–1293
  23. Neill M, Studer G, Le L, et al. The nature and extent of urinary morbidity in relation to prostate brachytherapy and urethral dosimetry. Brachytherapy. 2007;6:173–179
  24. Desai J, Stock RG, Stone NN, et al. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. Radiat Oncol Investig. 1998;6:135–141
  25. Keyes M, Miller S, Mirvan V, et al. Acute and late urinary toxicity in 606 prostate brachytherapy patients—The BC Cancer Agency experience. [Abstract] Brachytherapy. 2007;6:91

PII: S1538-4721(07)00282-6

doi: 10.1016/j.brachy.2007.12.002

Brachytherapy
Volume 7, Issue 1 , Pages 1-6 , January 2008

Article Tools

* Image Usage & Resolution